In a report issued on January 25, Rick Wise from Stifel Nicolaus reiterated a Buy rating on Hill-Rom (HRC), with a price target of $115. The company’s shares closed yesterday at $98.32.
According to TipRanks.com, Wise is a 5-star analyst with an average return of 12.3% and a 65.3% success rate. Wise covers the Healthcare sector, focusing on stocks such as Corindus Vascular Robotics, Obalon Therapeutics Inc, and Baxter International.
Currently, the analyst consensus on Hill-Rom is a Moderate Buy with an average price target of $111.83, implying a 13.7% upside from current levels. In a report issued on January 25, KeyBanc also maintained a Buy rating on the stock with a $114 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $105.78 and a one-year low of $78.16. Currently, Hill-Rom has an average volume of 610.2K.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. Most recently, in November 2018, Andreas Frank, the SVP, Pres. Front Line Care of HRC sold 7,454 shares for a total of $713,765.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hill-Rom Holdings, Inc. is a medical technology company, which focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following business segments: Patient Support System, Front Line Care, and Surgical Solutions.
